Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB
Rhea-AI Summary
Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) has announced its Q2 2025 financial results and its listing on the OTCQB market. The company reported an 85% increase in R&D spending compared to Q2 2024, primarily focused on their Gaucher and Progranulin programs.
The pre-clinical stage company, which develops small-molecule therapeutics for genetic diseases, has expanded its market presence through the OTCQB listing and has applied for DTC eligibility to enhance trading accessibility. Sharp is progressing toward Phase I clinical trials planned for 2026, utilizing its discovery platform that combines high-throughput screening technologies with computationally optimized compound libraries.
Positive
- 85% increase in R&D investment year-over-year
- Expansion to OTCQB market enhancing investor accessibility
- Progress toward Phase I clinical trials in 2026
- Pending DTC eligibility to improve trading efficiency
Negative
- Still in pre-clinical stage with no immediate revenue generation
- Increased R&D spending may impact cash burn rate
News Market Reaction
On the day this news was published, SHRXF declined 0.50%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condensed interim consolidated financial statements for the three and six months ended June 30, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated.
The Company also announces that its common shares are now trading under the symbol "SHRXF" on the OTCQB board of OTC Markets, a United States trading platform operated by the OTC Markets Group in New York (the "OTC Listing"). The Company's common shares will continue to trade on the Company's primary market, the TSX Venture Exchange, under the symbol "SHRX". This strategic expansion enhances Sharp's visibility, trading accessibility, and investor reach across North America, opening the door to a broader base of shareholders who the Company believes will recognize the potential of the Company's small-molecule therapeutics for genetic diseases.
Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our Q2 financial results show our continued investment in research and development programs, mainly our Gaucher and Progranulin programs. We spent
In connection with the OTC Listing, the Company has applied for eligibility with The Depository Trust Company ("DTC"). Once approved, Sharp's common shares will be eligible to be electronically cleared and settled through DTC and will be considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers. It reduces transactional costs for participating brokerage firms, enabling the stock to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements. DTC provides depository and book entry services, along with a settlement system for securities in the United States and across the globe. The organization is a member of the U.S. Federal Reserve System and a registered clearing agency with the U.S. Securities and Exchange Commission.
About Sharp Therapeutics Corp.
First-Choice Therapies for Genetic Diseases
Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.
For additional information on Sharp, please visit: www.sharptx.com.
Sharp Therapeutics Corp.
Scott Sneddon, PhD, JD
CEO/CSO
Email: scott@sharptx.com
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264564
FAQ
What is Sharp Therapeutics' (SHRXF) main business focus?
When will Sharp Therapeutics (SHRXF) begin Phase I clinical trials?
How much did Sharp Therapeutics increase their R&D spending in Q2 2025?
What is the significance of Sharp Therapeutics' OTCQB listing?
What technology does Sharp Therapeutics use for drug development?
